Work

First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)32010-x

Authors: M.G. Kris, T. Mok, S.-H.I. Ou, R.G. Martins, D.-W. Kim, Z. Goldberg, H. Zhang, I. Taylor, S.P. Letrent, P.A. Jänne

Institutions: Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, University of California, Irvine, University of Washington, Seoul National University Hospital, Pfizer (United States), Pfizer (China), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2999550753

FWCI: 1.426

Cites:

Cited by: 7

Related to: 10